Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clazosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.79 |
| ▸ | EDNRB | P24530 | 17/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clazosentan SCHEMBL29581324 | 1.00 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL1983603 | 1.00 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974629 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL26662037 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL31656331 | 0.97 | EDNRA (0.73) | EDNRAEDNRB | |
| SCHEMBL12022325 | 0.92 | EDNRA (0.68) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.92 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29409604 | 0.92 | EDNRA (0.80) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024162188-A1 | PAIN-RELIEVING AGENT FOR KNEE OSTEOARTHRITIS AND SHOULDER PERIARTHRITIS | 国立大学法人 東京大学 | 2024-08-08 | — | — | WO | claimed |
| EP-4329810-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | Perfuse Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. | 2024-02-22 | — | — | US | claimed |
| WO-2022232586-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | PERFUSE THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-20220273660-A1 | MEK INHIBITOR FOR TREATMENT OF STROKE | EDVINCE AB (SE) | 2022-09-01 | — | — | US | claimed |
| US-20260130890-A1 | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | PERFUSE THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622894-B2 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases | PERFUSE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260115491-A1 | AURICULAR VAGAL NERVE STIMULATION TO MITIGATE INFLAMMATORY COMPLICATIONS FOR BIOACTIVE AGENTS | AURENAR, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | REMD BIOTHERAPEUTICS INC (US) | 2026-04-21 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-4721742-A2 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Idorsia Pharmaceuticals Ltd (CH) | 2026-04-08 | — | — | EP | disclosed |
| CN-114146057-A | Pharmaceutical composition and use thereof | 斯皮内特赫拉公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
| US-20220049306-A1 | CARDIOVASCULAR DISEASE | GENINCODE UK, LTD. (GB) | 2022-02-17 | — | — | US | disclosed |
| EP-3954704-A1 | ANTIBODIES SPECIFIC FOR TGF-BETA | XOMA Technology Ltd. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273660-A1 | MEK INHIBITOR FOR TREATMENT OF STROKE | MAP3K2, MAP3K1, BRAF | EDNRA 1053/4885EDNRB 796/4885 |
| US-20260130890-A1 | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES | VEGFA, PDE6D, EDNRA | EDNRA 3/4885EDNRB 7/4885 |
| US-12606631-B2 | Antibodies which bind human endothelin receptor a (ETAR) | EDNRA, EDNRB, FCGR2A | EDNRA 1/4885EDNRB 2/4885 |
| US-20260115491-A1 | AURICULAR VAGAL NERVE STIMULATION TO MITIGATE INFLAMMATORY COMPLICATIONS FOR BIOACTIVE AGENTS | NGF, TRPV1, NTRK2 | EDNRA 1147/4885EDNRB 1641/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | EDNRA 26/4885EDNRB 7/4885 |
| US-20240058265-A1 | TREATMENT OF OCULAR DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
| US-12622894-B2 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases | VEGFA, PDE6D, LGALS3 | EDNRA 28/4885EDNRB 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.